• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Oncotype DX Genomic Prostate Score predicts for long-term clinical outcomes

Video

“This test requires just one millimeter of cancer on a biopsy on five consecutive slides,” says Eric A. Klein, MD.

JCO Precision Oncology recently published the paper, “GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific Mortality.” In this video, senior author Eric A. Klein, MD, discusses the background behind the study and what impresses him about the Oncotype DX Genomic Prostate Score. Klein is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic.

Related Videos
Blurred interior of hospital |  Image Credit: © jakkapan - stock.adobe.com
Laura Bukavina, MD, MPH, answers a question during a Zoom video interview
Image of kidneys | Image Credit: © peterschreiber.media - stock.adobe.com
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
DNA helix | Image Credit: © Siarhei - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.